Latest research report on “PD-1 and PD-L1 Inhibitors Market” now available at high quality database of ReportsnReports.com with market size, share, trends, competitive and statistical analysis. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample Copy @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5613290
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
This report contains market size and forecasts of PD-1 and PD-L1 Inhibitors in global, including the following market information:
Global PD-1 and PD-L1 Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global PD-1 and PD-L1 Inhibitors Market Sales, 2017-2022, 2023-2028, (L)
Global top five PD-1 and PD-L1 Inhibitors companies in 2021 (%)
The global PD-1 and PD-L1 Inhibitors market was valued at 40690 million in 2021 and is projected to reach US$ 140220 million by 2028, at a CAGR of 19.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
PD-1 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of PD-1 and PD-L1 Inhibitors include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the PD-1 and PD-L1 Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-1 and PD-L1 Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (L)
Global PD-1 and PD-L1 Inhibitors Market Segment Percentages, by Type, 2021 (%)
– PD-1 Inhibitors
– PD-L1 Inhibitors
Global PD-1 and PD-L1 Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (L)
Global PD-1 and PD-L1 Inhibitors Market Segment Percentages, by Application, 2021 (%)
– Solid Tumors
– Blood-related Tumors
Global PD-1 and PD-L1 Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (L)
Global PD-1 and PD-L1 Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
– North America
– – US
– – Canada
– – Mexico
– – Germany
– – France
– – U.K.
– – Italy
– – Russia
– – Nordic Countries
– – Benelux
– – Rest of Europe
– – China
– – Japan
– – South Korea
– – Southeast Asia
– – India
– – Rest of Asia
– South America
– – Brazil
– – Argentina
– – Rest of South America
– Middle East & Africa
– – Turkey
– – Israel
– – Saudi Arabia
– – UAE
– – Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies PD-1 and PD-L1 Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies PD-1 and PD-L1 Inhibitors revenues share in global market, 2021 (%)
Key companies PD-1 and PD-L1 Inhibitors sales in global market, 2017-2022 (Estimated), (L)
Key companies PD-1 and PD-L1 Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
– Bristol-Myers Squibb
– Ono Pharmaceutical
– Hengrui Medicine
– Junshi Biosciences
– Merck KGaA
More information about Discount offers (20% or More) @ https://www.reportsnreports.com/contacts/discount.aspx?name=5613290
About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
We provide 24/7 online and offline support to our customers.
E-mail: [email protected]
Phone: +1 888 391 5441